Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience across drug development, treatment, and outcomes. AXPAXLI™ (also known as OTX-TKI), an investigational axitinib hydrogel administered by intravitreal injection, is Ocular’s leading investigational candidate for retinal disease, based on its proprietary ELUTYX™ technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and has potential applications across other retinal diseases such as non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME).
- Founded
- 2006
- Company size
- 201-500
- Headquarters
- Bedford, Massachusetts, US
- Funding
- Post Ipo Equity
Hiring activity
- Open roles
- 7
- Posted in the last 30 days
- 7
- Most common roles
- Account ManagerBusiness Operations ManagerAccountant
Updated 6h ago
What Ocular Therapeutix says about its culture
What Ocular Therapeutix says it offers, drawn from its own website.
Check if you fitOpens the career fit test.
To redefine treatment for the leading causes of blindness and preserve vision for the long term
Integrity
“Above all, we lead with integrity.”Source
Information sharing to enhance speed & agility; engage proactively & openly
“Information sharing to enhance speed & agility. Engage proactively & openly”Source
Accountability
“Accept responsibility, deliver on commitments”Source
Urgency and continuous improvement
“High sense of urgency, continuous improvement”Source
They say people do well here who…
- Driven, goal-focused professionals eager to thrive in an entrepreneurial environment
Quoted from Ocular Therapeutix's own website. TeaKo does not verify these claims.
Latest openings
7 open roles at Ocular Therapeutix. Members see each one.
